atorvastatin has been researched along with Arteriosclerosis in 80 studies
*Arteriosclerosis: Thickening and loss of elasticity of the walls of ARTERIES of all sizes. There are many forms classified by the types of lesions and arteries involved, such as ATHEROSCLEROSIS with fatty lesions in the ARTERIAL INTIMA of medium and large muscular arteries. [MeSH]
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (8.75) | 18.2507 |
| 2000's | 70 (87.50) | 29.6817 |
| 2010's | 3 (3.75) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Buckett, L; Davidson, R; Holdgate, G; McCormick, A; McTaggart, F; Schneck, D; Smith, G; Warwick, M | 1 |
| Beleford, DT; Diab, M; Long, RK; Malloy, MJ; Qubty, WF; Shieh, JT | 1 |
| Balakhonova, T; Boytsov, S; Deev, A; Kolos, I; Shariya, M; Skrypnik, D; Troitskiy, A; Tvorogova, T | 1 |
| Chowdhury, S; Mukherjee, S; Mukhopadhyay, P; Pandit, K | 1 |
| Cheng, QL; Ye, P; Zhao, JH | 1 |
| Delsing, DJ; Havekes, LM; Jukema, JW; Princen, HM; Puppels, GJ; van de Poll, SW; van der Laarse, A | 1 |
| Dixon, JL; Shen, S; Sturek, M; Sun, GY; Vuchetich, JP; Wysocka, E | 1 |
| Shah, PK | 1 |
| Coyle, LC; Flaherty, PJ; Kent, SM; Markwood, TT; Taylor, AJ; Vernalis, MN | 1 |
| Harman, SM; Hecht, HS | 1 |
| Amâncio, RF; Chapman, MJ; Maranhão, RC; Ramires, JA; Santos, RD; Sposito, AC | 1 |
| Delsing, DJ; Havekes, LM; Princen, HM; Puppels, GJ; van de Poll, SW; van der Laarse, A; Wouter Jukema, J | 1 |
| Beaudry, JA; Bhat, BG; Butteiger, DN; Hall, KA; Keller, BT; Luo, Y; Napawan, N; Null, CL; Rapp, SR | 1 |
| Delsing, DJ; Emeis, JJ; Havekes, LM; Jukema, JW; Princen, HM; van de Wiel, MA; van der Laarse, A | 1 |
| Aragoncillo, P; Cachofeiro, V; Cediel, E; de las Heras, N; Díaz, C; Hernández, G; Lahera, V; Oubiña, MP; Sanz-Rosa, D | 1 |
| de Boo, T; Kastelein, JJ; Smilde, TJ; Stalenhoef, AF; Trip, MD; van Wissen, S | 1 |
| Dechend, R; Dietz, R; Gieffers, J; Joerres, A; Luft, FC; Maass, M; Rupp, J | 1 |
| Aviles, RJ; Brennan, ML; Fu, X; Hazen, SL; Penn, MS; Shishehbor, MH; Sprecher, DL | 1 |
| Burger, F; Graber, P; Kwak, BR; Lüscher, TF; Mach, F; Matter, CM; Mulhaupt, F; Pelli, G; Veillard, NR | 1 |
| de Groot, E; Hutten, BA; Kastelein, JJ; Smilde, TJ; Stalenhoef, AF; van Wissen, S | 1 |
| Berger, T; Daniel, WG; Garlichs, CD; Ludwig, J; Raaz, D; Reiss, C; Steinkasserer, A; Stumpf, C; Tantawi, O; Weng, A; Yilmaz, A | 1 |
| Ayan, F; Curgunlu, A; Ertürk, N; Karter, Y; Mihmanli, I; Vehid, S | 1 |
| Fathi, R; Haluska, B; Isbel, N; Johnson, D; Marwick, TH; Short, L | 1 |
| Coyle, LC; Flaherty, PJ; Kent, SM; Markwood, TT; Taylor, AJ | 1 |
| Jukema, JW; van der Hoorn, JW | 1 |
| de Grooth, GJ; Fruchart, JC; Kastelein, JJ; Klerkx, AH; Kuivenhoven, JA; Smilde, TJ; Stalenhoef, AF; Van Wissen, S; Zwinderman, AH | 1 |
| Barter, PJ; Bonnet, J; Cheung, RC; Kallend, D; Morrell, JM; Raza, A; Schuster, H; Stender, S; Watkins, C | 1 |
| Andreassen, AK; Aukrust, P; Gullestad, L; Hognestad, A; Holm, T; Kjekshus, JK; Semb, AG; Stokke, O; Wergeland, R | 1 |
| Bell, PR; Loftus, IM; Molloy, KJ; Naylor, AR; Schwalbe, EC; Thompson, MM | 1 |
| Ganz, P; Kinlay, S; Libby, P; Olsson, AG; Rifai, N; Sasiela, WJ; Schwartz, GG; Szarek, M | 1 |
| Levy, Y | 1 |
| Emeis, SJ; Kleemann, R; Kooistra, T; Offerman, EH; Princen, HM; Szalai, AJ; Verschuren, L | 1 |
| Benz, R; Suter, PM | 1 |
| Adams, GJ; Ballantyne, CM; Greene, J; Harrist, R; Insull, W; Karmonik, C; Kimball, KT; Morrisett, JD; Vick, GW | 1 |
| Bays, HE; Blasetto, JW; Cain, VA; Deedwania, PC; Hunninghake, DB; Jones, PH | 1 |
| Ayaori, M; Fayad, ZA; Higashi, K; Iwamoto, N; Kihara, T; Kusuhara, M; Momiyama, Y; Nagata, M; Nakamura, H; Ogura, M; Ohmori, R; Ohsuzu, F; Sawada, S; Tamai, S; Taniguchi, H; Yonemura, A | 1 |
| Djanani, A; Feistritzer, C; Kaneider, NC; Mosheimer, BA; Patsch, JR; Sturn, DH; Wiedermann, CJ | 1 |
| Almeida, EA; Carneiro, A; Jorge, M; Jorge, PA; Ozaki, MR | 1 |
| Ahn, JY; Choi, IS; Chung, WJ; Han, SH; Koh, KK; Quon, MJ; Seo, YH; Shin, EK | 1 |
| Kakuta, H; Kihara, R; Shimano, H; Suzuki, M; Tada-Iida, K; Takahashi, A; Yamada, N; Yokoo, T | 1 |
| Bennett, MR; Davenport, AP; Kuc, RE; Maguire, JJ; Stoneman, VE; Wiley, KE | 1 |
| Ho, W; Huo, Y; Liu, ZP; Meng, L | 1 |
| Hatta, T; Hushiki, S; Irie, H; Kobara, M; Kuwahara, N; Matsubara, H; Nakata, T; Narumiya, H; Sasaki, S; Takeda, K; Tatsumi, T | 1 |
| Rubba, P | 1 |
| Andrys, C; Jamborova, G; Micuda, S; Nachtigal, P; Pospechova, K; Pospisilova, N; Semecky, V; Solichova, D; Zdansky, P | 1 |
| Abe, Y; Ballantyne, CM; Dunn, K; Gotto, AM; Hackman, A; Insull, W; Pownall, H; Smith, L | 1 |
| Wehmeier, T; Ziajka, PE | 1 |
| Bakker-Arkema, RG; Black, DM; Brown, AS; Campbell, CF; Guthrie, R; Henley, RW; Koren, M; McLain, R; Woo, W; Yellen, L | 1 |
| Bachorik, PS | 1 |
| Alfon, J; Badimon, L; Berrozpe, M; Guasch, JF | 1 |
| Joffe, BI; Kotze, MJ; Pilcher, GJ; Raal, FJ; Veller, MG | 1 |
| Baker, JC; Emeson, EE; Hall, D; Jamal, S; Johnston, TP; Palmer, WK | 1 |
| Arbustini, E; Cofrancesco, E; Cortellaro, M; Gabrielli, L; Tremoli, E | 1 |
| Kastelein, JJ; Smilde, TJ; Stalenhoef, AF; van den Berkmortel, FW; van Langen, H; Wollersheim, H | 1 |
| Arnaboldi, L; Bellosta, S; Bernini, F; Corsini, A; Ferri, N; Paoletti, R | 1 |
| Armitage, J; Betteridge, DJ; Colhoun, H | 1 |
| Ose, L; Risberg, K; Svilaas, A; Thoresen, M | 1 |
| Stein, EA | 1 |
| Harangi, M; Paragh, G | 1 |
| Arai, Y; Funatsu, T; Kakuta, H; Miyata, K; Suzuki, K; Tanaka, H | 1 |
| Bachmann, GA; Callister, TQ; Davidson, M; Kafonek, S; Laskey, R; Pittman, D; Raggi, P; Scott, R; Welty, FK | 1 |
| Wierzbicki, AS | 2 |
| Kajinami, K; Takekoshi, N | 1 |
| Beckmann, S; Bocksch, W; Gross, M; Hausmann, D; Karsch, KR; Koschyk, DH; Kreuzer, J; Schartl, M; Voelker, W | 1 |
| Susekov, AV | 1 |
| Libby, P | 1 |
| Criqui, MH | 1 |
| Bakker Schut, TC; Delsing, DJ; Havekes, LM; Jukema, JW; Princen, HM; Puppels, GJ; Römer, TJ; van De Poll, SW; van Der Laarse, A; Volger, OL | 1 |
| Alfón, J; Badimon, L; Berrozpe, M; Martínez-González, J | 1 |
| Aparicio, C; Blanco-Colio, LM; Díaz, C; Egido, J; Gerique, JG; Gómez-Hernández, A; Hernández, G; Hernández-Presa, MA; Hernández-Vargas, P; Martín-Ventura, JL; Mas, S; Ortega, L; Ortego, M; Tuñón, J; Vivanco, F | 1 |
| Gussenhoven, EJ; Hagenaars, T; Poldermans, D; van der Lugt, A; van Urk, H | 1 |
| Celik, S; Erdöl, C; Kural, BV; Orem, A; Orem, C; Uydu, HA | 1 |
| Bruckert, E; Gagné, C; Gaudet, D | 1 |
| Chapman, MJ; Dupuis, R; Egger, P; Guerin, M; Le Goff, W; Soudant, C; van Tol, A | 1 |
11 review(s) available for atorvastatin and Arteriosclerosis
| Article | Year |
|---|---|
Amlodipine and atorvastatin in atherosclerosis: a review of the potential of combination therapy.
Topics: Amlodipine; Animals; Arteriosclerosis; Atorvastatin; Calcium Channel Blockers; Combined Modality Therapy; Heptanoic Acids; Humans; Hypertension; Hypolipidemic Agents; Pyrroles | 2004 |
[Low HDL-cholesterol, high triglycerides--well known but often ignored].
Topics: Adult; Aged; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Cholesterol, HDL; Clofibric Acid; Combined Modality Therapy; Exercise; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Male; Metabolic Syndrome; Niacin; Pyrroles; Risk Factors; Smoking Cessation; Triglycerides; Weight Loss; World Health Organization | 2004 |
Effects of atorvastatin on the different phases of atherogenesis.
Topics: Arteriosclerosis; Atorvastatin; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles | 2007 |
Peripheral neuropathy and lipid-lowering therapy.
Topics: Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Drug Therapy, Combination; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Middle Aged; Naphthalenes; Niacin; Peripheral Nervous System Diseases; Pravastatin; Pyrroles; Simvastatin | 1998 |
[The role of HDL in the prevention of cardiovascular events].
Topics: Anticholesteremic Agents; Arteriosclerosis; Aryldialkylphosphatase; Atorvastatin; Cholesterol, HDL; Esterases; Fatty Acids, Monounsaturated; Fluvastatin; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Lipid Peroxidation; Lovastatin; Phosphatidylcholine-Sterol O-Acyltransferase; Pyrroles; Simvastatin | 2001 |
[Atorvastatin (Lipitor): a review of its pharmacological and clinical profile].
Topics: Animals; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Cholesterol, LDL; Clinical Trials as Topic; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipidemias; Lipoproteins, VLDL; Liver; Pyrroles; Receptors, LDL; Triglycerides | 2001 |
Atorvastatin.
Topics: Animals; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Cost-Benefit Analysis; Drug Interactions; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrroles | 2001 |
[Atorvastatin].
Topics: Animals; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Cholesterol, LDL; Coronary Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pyrroles; Randomized Controlled Trials as Topic | 2001 |
Synthetic statins: more data on newer lipid-lowering agents.
Topics: Arteriosclerosis; Atorvastatin; Clinical Trials as Topic; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Lipids; Pyridines; Pyrroles; Simvastatin | 2001 |
[Substantiation of increasing doses of statins in clinical practice].
Topics: Adult; Aged; Angiography; Animals; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Clinical Trials as Topic; Colestipol; Coronary Disease; Dogs; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Lipids; Lovastatin; Male; Meta-Analysis as Topic; Middle Aged; Primates; Prospective Studies; Pyrroles; Retrospective Studies; Risk Factors; Simvastatin; Time Factors | 2001 |
Systemic atherosclerosis risk and the mandate for intervention in atherosclerotic peripheral arterial disease.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Arterial Occlusive Diseases; Arteriosclerosis; Atorvastatin; Cholesterol; Clinical Trials as Topic; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Risk Factors; Survival Rate | 2001 |
25 trial(s) available for atorvastatin and Arteriosclerosis
| Article | Year |
|---|---|
Modern medical treatment with or without carotid endarterectomy for severe asymptomatic carotid atherosclerosis.
Topics: Aged; Amlodipine; Arteriosclerosis; Atorvastatin; Carotid Artery Diseases; Endarterectomy, Carotid; Female; Follow-Up Studies; Humans; Hydrochlorothiazide; Life Style; Male | 2015 |
Atorvastatin improves arterial stiffness in normotensive normolipidaemic persons with type 2 diabetes.
Topics: Adult; Aged; Ankle; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Blood Flow Velocity; Blood Pressure; Body Mass Index; Brachial Artery; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Male; Middle Aged; Pulsatile Flow; Pyrroles; Treatment Outcome | 2008 |
ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness.
Topics: Adult; Arteriosclerosis; Atorvastatin; Carotid Arteries; Cholesterol; Cholesterol, LDL; Endpoint Determination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipids; Male; Middle Aged; Pravastatin; Pyrroles; Tunica Intima; Ultrasonography | 2002 |
Atorvastatin enhances the plasma clearance of chylomicron-like emulsions in subjects with atherogenic dyslipidemia: relevance to the in vivo metabolism of triglyceride-rich lipoproteins.
Topics: Adult; Aged; Analysis of Variance; Arteriosclerosis; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Chylomicrons; Dose-Response Relationship, Drug; Drug Administration Schedule; Fat Emulsions, Intravenous; Female; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Particle Size; Probability; Pyrroles; Triglycerides | 2003 |
Long term statin treatment reduces lipoprotein(a) concentrations in heterozygous familial hypercholesterolaemia.
Topics: Arteriosclerosis; Atorvastatin; Carotid Arteries; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipoprotein(a); Male; Middle Aged; Pyrroles; Simvastatin | 2003 |
Statins promote potent systemic antioxidant effects through specific inflammatory pathways.
Topics: Antioxidants; Arteriosclerosis; Atorvastatin; Biomarkers; C-Reactive Protein; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Inflammation; Lipoproteins; Male; Middle Aged; Oxidation-Reduction; Prospective Studies; Pyrroles; Reactive Oxygen Species; Signal Transduction; Statistics, Nonparametric; Tyrosine | 2003 |
The significance of femoral intima-media thickness and plaque scoring in the Atorvastatin versus Simvastatin on Atherosclerosis Progression (ASAP) study.
Topics: Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Carotid Arteries; Double-Blind Method; Female; Femoral Artery; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Pyrroles; Simvastatin; Tunica Intima; Tunica Media | 2003 |
Effects of low and high doses of atorvastatin on arterial compliance.
Topics: Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Carotid Artery, Common; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Compliance; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Triglycerides; Ultrasonography, Doppler, Color; Ultrasonography, Interventional | 2003 |
The effect of long-term aggressive lipid lowering on ischemic and atherosclerotic burden in patients with chronic kidney disease.
Topics: Aged; Analysis of Variance; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Brachial Artery; Carotid Artery, Common; Coronary Disease; Female; Heptanoic Acids; Humans; Hyperlipidemias; Kidney Failure, Chronic; Lipids; Male; Middle Aged; Prospective Studies; Pyrroles; Risk Factors; Tunica Intima; Tunica Media; Ultrasonography | 2004 |
Marked low-density lipoprotein cholesterol reduction below current national cholesterol education program targets provides the greatest reduction in carotid atherosclerosis.
Topics: Arteriosclerosis; Atorvastatin; C-Reactive Protein; Carotid Artery Diseases; Cholesterol, LDL; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Practice Guidelines as Topic; Pravastatin; Pyrroles; Tunica Intima; Ultrasonography | 2004 |
The relationship between cholesteryl ester transfer protein levels and risk factor profile in patients with familial hypercholesterolemia.
Topics: Administration, Oral; Analysis of Variance; Arteriosclerosis; Atorvastatin; Carrier Proteins; Cholesterol Ester Transfer Proteins; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Glycoproteins; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Linear Models; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Probability; Prognosis; Pyrroles; Reference Values; Risk Assessment; Severity of Illness Index; Simvastatin; Treatment Outcome; Tunica Media | 2004 |
Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) study.
Topics: Aged; Arteriosclerosis; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus, Type 2; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Logistic Models; Male; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Triglycerides | 2004 |
Effects of conventional and aggressive statin treatment on markers of endothelial function and inflammation.
Topics: Arteriosclerosis; Atorvastatin; C-Reactive Protein; Chronic Disease; Coronary Artery Disease; E-Selectin; Female; Fibrinogen; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Middle Aged; Nitric Oxide; Pyrroles; Simvastatin; Treatment Outcome | 2004 |
Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study.
Topics: Aged; Angina Pectoris; Angina, Unstable; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Biomarkers; CD40 Ligand; Double-Blind Method; Female; Heart Arrest; Heptanoic Acids; Humans; Inflammation Mediators; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Pyrroles; Recurrence; Risk; Solubility; Treatment Outcome | 2004 |
Tracking regression and progression of atherosclerosis in human carotid arteries using high-resolution magnetic resonance imaging.
Topics: Aged; Aged, 80 and over; Algorithms; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Carotid Arteries; Carotid Artery Diseases; Disease Progression; Female; Follow-Up Studies; Heptanoic Acids; Humans; Image Enhancement; Magnetic Resonance Imaging; Male; Middle Aged; Observer Variation; Pilot Projects; Pravastatin; Pyrroles; Reproducibility of Results; Simvastatin | 2004 |
Effects of rosuvastatin, atorvastatin, simvastatin, and pravastatin on atherogenic dyslipidemia in patients with characteristics of the metabolic syndrome.
Topics: Adult; Aged; Aged, 80 and over; Arteriosclerosis; Atorvastatin; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Metabolic Syndrome; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2005 |
Effect of lipid-lowering therapy with atorvastatin on atherosclerotic aortic plaques detected by noninvasive magnetic resonance imaging.
Topics: Aged; Anticholesteremic Agents; Aorta, Abdominal; Aorta, Thoracic; Aortic Diseases; Arteriosclerosis; Atorvastatin; Cholesterol, LDL; Disease Progression; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Image Enhancement; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Male; Middle Aged; Pyrroles; Treatment Outcome | 2005 |
Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemia.
Topics: Arteriosclerosis; Atorvastatin; Brachial Artery; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combination; Female; Fenofibrate; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemia, Familial Combined; Hypolipidemic Agents; Lipids; Male; Middle Aged; Myocardial Ischemia; Pyrroles; Treatment Outcome; Ultrasonography | 2005 |
Treating patients with documented atherosclerosis to National Cholesterol Education Program-recommended low-density-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin.
Topics: Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Cholesterol, LDL; Colestipol; Combined Modality Therapy; Diet, Fat-Restricted; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Indoles; Lovastatin; Male; Pyrroles; Simvastatin; Treatment Outcome | 1998 |
The effect of cholesterol lowering on carotid and femoral artery wall stiffness and thickness in patients with familial hypercholesterolaemia.
Topics: Adult; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Blood Pressure; Carotid Arteries; Cholesterol, HDL; Cholesterol, LDL; Elasticity; Family Health; Female; Femoral Artery; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Pyrroles; Simvastatin; Triglycerides; Tunica Intima | 2000 |
Aggressive versus moderate lipid-lowering therapy in postmenopausal women with hypercholesterolemia: Rationale and design of the Beyond Endorsed Lipid Lowering with EBT Scanning (BELLES) trial.
Topics: Aged; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Cholesterol, LDL; Coronary Vessels; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Middle Aged; Postmenopause; Pravastatin; Prognosis; Prospective Studies; Pyrroles; Reproducibility of Results; Safety; Tomography, X-Ray Computed | 2001 |
Use of intravascular ultrasound to compare effects of different strategies of lipid-lowering therapy on plaque volume and composition in patients with coronary artery disease.
Topics: Anticholesteremic Agents; Arteriosclerosis; Arthralgia; Atorvastatin; Butyrates; Cholesterol; Cholesterol, HDL; Cholestyramine Resin; Coronary Disease; Creatinine; Exanthema; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Patient Dropouts; Pyrroles; Treatment Outcome; Triglycerides; Ultrasonography, Interventional; Venous Thrombosis | 2001 |
Rationale and design for the SARIS trial; effect of statin on atherosclerosis and vascular remodeling assessed with intravascular sonography. Effect of Statin on Atherosclerosis and vascular Remodeling assessed with Intravascular Sonography.
Topics: Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Cholesterol; Coronary Circulation; Echocardiography, Stress; Female; Heptanoic Acids; Humans; Hyperplasia; Male; Multicenter Studies as Topic; Prospective Studies; Pyrroles; Sensitivity and Specificity; Tunica Intima | 2001 |
Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia.
Topics: Adolescent; Adult; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Azetidines; Blood Component Removal; Child; Cholesterol, LDL; Creatine Kinase; Diet Therapy; Dose-Response Relationship, Drug; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Homozygote; Humans; Hyperlipoproteinemia Type II; Liver Function Tests; Male; Pyrroles; Simvastatin; Treatment Outcome | 2002 |
Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux.
Topics: Adult; Aged; Apolipoprotein B-100; Apolipoproteins B; Arteriosclerosis; Atorvastatin; Carrier Proteins; Cholesterol; Cholesterol Ester Transfer Proteins; Dose-Response Relationship, Drug; Female; Glycoproteins; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipoproteins; Lipoproteins, HDL; Lipoproteins, IDL; Lipoproteins, LDL; Lipoproteins, VLDL; Liver; Male; Membrane Proteins; Middle Aged; Phospholipid Transfer Proteins; Pyrroles | 2002 |
44 other study(ies) available for atorvastatin and Arteriosclerosis
| Article | Year |
|---|---|
Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor.
Topics: Animals; Arteriosclerosis; Cholesterol, LDL; Clinical Trials as Topic; Drug Evaluation, Preclinical; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Molecular Structure; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2001 |
Schimke immunoosseous dysplasia and management considerations for vascular risks.
Topics: Anticholesteremic Agents; Antihypertensive Agents; Arteriosclerosis; Atorvastatin; Benzazepines; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Child; Disease Management; DNA Helicases; Dyslipidemias; Female; Gene Expression; Headache; Humans; Hypertension; Mutation; Nephrotic Syndrome; Osteochondrodysplasias; Primary Immunodeficiency Diseases; Propranolol; Pulmonary Embolism | 2019 |
[The effects of atorvastatin on aging kidney].
Topics: Aging; Animals; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Female; Heptanoic Acids; Kidney; Kidney Diseases; Pyrroles; Rats; Rats, Wistar; Renal Artery | 2011 |
Raman spectroscopic investigation of atorvastatin, amlodipine, and both on atherosclerotic plaque development in APOE*3 Leiden transgenic mice.
Topics: Amlodipine; Animals; Antihypertensive Agents; Aorta; Apolipoprotein E3; Apolipoproteins E; Arteriosclerosis; Atorvastatin; Cholesterol; Disease Models, Animal; Drug Synergism; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mice; Mice, Transgenic; Pyrroles; Spectrum Analysis, Raman | 2002 |
Increased atherosclerosis in diabetic dyslipidemic swine: protection by atorvastatin involves decreased VLDL triglycerides but minimal effects on the lipoprotein profile.
Topics: Animals; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Blood Glucose; Cholesterol; Collagen; Diabetes Mellitus, Experimental; Diet, Atherogenic; Fasting; Heptanoic Acids; Hyperlipidemias; Insulin; Lipoproteins, VLDL; Liver; Male; Pyrroles; Swine; Swine, Miniature; Triglycerides; Vitamin A; Vitamin E | 2002 |
Low-density lipoprotein lowering and atherosclerosis progression: does more mean less?
Topics: Arteriosclerosis; Atorvastatin; Carotid Arteries; Cholesterol; Cholesterol, LDL; Disease Progression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Pravastatin; Pyrroles; Ultrasonography | 2002 |
Zeroing in on how low cholesterol should go.
Topics: Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Cholesterol, LDL; Heptanoic Acids; Humans; Pravastatin; Pyrroles; Risk Factors | 2002 |
Comparison of the effects of atorvastatin versus simvastatin on subclinical atherosclerosis in primary preventionas determined by electronbeam tomography.
Topics: Analysis of Variance; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Chi-Square Distribution; Disease Progression; Female; Heptanoic Acids; Humans; Lipids; Male; Middle Aged; Niacin; Primary Prevention; Pyrroles; Risk Factors; Simvastatin; Tomography, X-Ray Computed; Treatment Outcome | 2003 |
Effects of amlodipine, atorvastatin and combination of both on advanced atherosclerotic plaque in APOE*3-Leiden transgenic mice.
Topics: Amlodipine; Animals; Anticholesteremic Agents; Aorta; Apolipoproteins E; Arteriosclerosis; Atorvastatin; Calcium Channel Blockers; Cholesterol; Heptanoic Acids; Humans; Mice; Mice, Transgenic; Pyrroles; Triglycerides | 2003 |
Inhibition of ileal bile acid transport and reduced atherosclerosis in apoE-/- mice by SC-435.
Topics: Animals; Apolipoproteins E; Arteriosclerosis; Atorvastatin; Bile Acids and Salts; Biological Transport; Cells, Cultured; Cricetinae; Cyclic N-Oxides; Enzyme Inhibitors; Gene Deletion; Heptanoic Acids; Humans; Ileum; Male; Mice; Mice, Knockout; Organic Anion Transporters, Sodium-Dependent; Pyrroles; Symporters; Tropanes | 2003 |
Differential effects of amlodipine and atorvastatin treatment and their combination on atherosclerosis in ApoE*3-Leiden transgenic mice.
Topics: Amlodipine; Animals; Aorta, Thoracic; Apolipoprotein E3; Apolipoproteins E; Arteriosclerosis; Atorvastatin; Blood Pressure; Calcium Channel Blockers; Cholesterol; Cholesterol, Dietary; Drug Therapy, Combination; Female; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mice; Mice, Transgenic; Pyrroles | 2003 |
Synergistic effect of angiotensin-converting enzyme (ACE) and 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase inhibition on inflammatory markers in atherosclerotic rabbits.
Topics: Acyl Coenzyme A; Angiotensin-Converting Enzyme Inhibitors; Animals; Aorta, Thoracic; Arteriosclerosis; Atorvastatin; Blood Pressure; Drug Synergism; Drug Therapy, Combination; Enzyme Inhibitors; Fibrinolysis; Heptanoic Acids; Hypercholesterolemia; In Vitro Techniques; Inflammation Mediators; Male; Pyrroles; Quinapril; Rabbits; Tetrahydroisoquinolines; Tunica Intima; Vasodilation | 2003 |
Hydroxymethylglutaryl coenzyme A reductase inhibition reduces Chlamydia pneumoniae-induced cell interaction and activation.
Topics: Animals; Arteriosclerosis; Atorvastatin; Cell Communication; Cell Membrane; Cells, Cultured; Chemokines; Chlamydophila Infections; Chlamydophila pneumoniae; Coculture Techniques; Dose-Response Relationship, Drug; Enzyme Activation; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Macrophages; Mice; Mice, Knockout; Muscle, Smooth, Vascular; NF-kappa B; Protein Prenylation; Pyridines; Pyrroles; rac1 GTP-Binding Protein; Reactive Oxygen Species; rhoA GTP-Binding Protein; RNA, Messenger; Signal Transduction | 2003 |
Statins (HMG-CoA reductase inhibitors) reduce CD40 expression in human vascular cells.
Topics: Animals; Arteriosclerosis; Atorvastatin; Blotting, Western; CD40 Antigens; Cells, Cultured; Depression, Chemical; Dose-Response Relationship, Drug; Endothelial Cells; Fibroblasts; Flow Cytometry; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Interferon-gamma; Lovastatin; Macrophages; Mevalonic Acid; Mice; Muscle, Smooth, Vascular; Nitric Oxide Synthase; Pravastatin; Pyrroles; Receptors, Cytoplasmic and Nuclear; Recombinant Proteins; Simvastatin; Transcription Factors | 2003 |
HMG-CoA reductase inhibitors suppress maturation of human dendritic cells: new implications for atherosclerosis.
Topics: Adjuvants, Immunologic; Antigens, CD; Arteriosclerosis; Atorvastatin; B7-2 Antigen; Bone Marrow Cells; CD83 Antigen; Cell Survival; Cells, Cultured; Dendritic Cells; Flow Cytometry; Heptanoic Acids; HLA-DR Antigens; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunoglobulins; Lymphocyte Culture Test, Mixed; Membrane Glycoproteins; Pyrroles; Receptors, CCR7; Receptors, Chemokine; Simvastatin; Time Factors; Tumor Necrosis Factor Receptor Superfamily, Member 7 | 2004 |
Clash of the statins? A trial pitting two popular statins against each other helps answer a far more important question: how low should cholesterol go?
Topics: Arteriosclerosis; Atorvastatin; Cholesterol, LDL; Clinical Trials as Topic; Disease Progression; Heptanoic Acids; Humans; Hypolipidemic Agents; Myocardial Infarction; Pravastatin; Pyrroles; Reference Values; Stroke | 2004 |
Is Lipitor better than Pravachol?
Topics: Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Cholesterol, LDL; Heptanoic Acids; Humans; Pravastatin; Pyrroles | 2004 |
What to do about cholesterol now. Here's the take-home message from startling new research findings.
Topics: Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Biomedical Research; Cholesterol, HDL; Cholesterol, LDL; Heptanoic Acids; Humans; Pravastatin; Pyrroles | 2004 |
Comparison of levels of matrix metalloproteinases, tissue inhibitor of metalloproteinases, interleukins, and tissue necrosis factor in carotid endarterectomy specimens from patients on versus not on statins preoperatively.
Topics: Aged; Aged, 80 and over; Arteriosclerosis; Atorvastatin; Carotid Artery Diseases; Endarterectomy, Carotid; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Interleukins; Male; Matrix Metalloproteinases; Middle Aged; Pravastatin; Pyrroles; Simvastatin; Tissue Inhibitor of Metalloproteinases; Tumor Necrosis Factor-alpha; Ultrasonography | 2004 |
Beyond cholesterol lowering: effect of statins on markers of cardiovascular disease.
Topics: Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; C-Reactive Protein; Fibrinogen; Heptanoic Acids; Humans; Hypercholesterolemia; Pyrroles; Risk Factors | 2004 |
Effect of low dose atorvastatin versus diet-induced cholesterol lowering on atherosclerotic lesion progression and inflammation in apolipoprotein E*3-Leiden transgenic mice.
Topics: Animals; Anticholesteremic Agents; Aorta; Apolipoprotein E3; Apolipoproteins E; Arteriosclerosis; Atorvastatin; Biomarkers; C-Reactive Protein; Cholesterol; Diet; Diet, Atherogenic; Drug Administration Schedule; Female; Heptanoic Acids; Inflammation; Male; Mice; Mice, Transgenic; Pyrroles; Serum Amyloid A Protein | 2005 |
CD40-ligand-dependent induction of COX-2 gene expression in endothelial cells by activated platelets: inhibitory effects of atorvastatin.
Topics: Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Blood Platelets; CD40 Antigens; CD40 Ligand; Cells, Cultured; Cyclooxygenase 2; Endothelial Cells; Gene Expression Regulation; Heptanoic Acids; Humans; Membrane Proteins; Platelet Activation; Prostaglandin-Endoperoxide Synthases; Pyrroles | 2005 |
[Effects of atorvastatin, fluvastatin, pravastatin, and simvastatin on endothelial function, lipid peroxidation, and aortic atherosclerosis in hypercholesterolemic rabbits].
Topics: Animals; Anticholesteremic Agents; Aortic Diseases; Arteriosclerosis; Atorvastatin; Cholesterol; Cholesterol, LDL; Endothelium, Vascular; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Hypercholesterolemia; Indoles; Lipid Peroxidation; Male; Malondialdehyde; Pravastatin; Pyrroles; Rabbits; Simvastatin | 2005 |
Effects of atorvastatin on glucose metabolism and insulin resistance in KK/Ay mice.
Topics: Animals; Arteriosclerosis; Atorvastatin; Biomarkers; Blood Glucose; Blotting, Northern; CCAAT-Enhancer-Binding Proteins; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; DNA-Binding Proteins; Gene Expression Regulation, Enzymologic; Glucose Tolerance Test; Glucose-6-Phosphatase; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin Resistance; Lipids; Male; Mice; Mice, Inbred Strains; Pyrroles; RNA, Messenger; Sterol Regulatory Element Binding Protein 1; Transcription Factors | 2005 |
Endothelin-mediated vasoconstriction in early atherosclerosis is markedly increased in ApoE-/- mouse but prevented by atorvastatin.
Topics: Animals; Apolipoproteins E; Arteriosclerosis; Atorvastatin; Endothelins; Female; Heptanoic Acids; Homozygote; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Pyrroles; Time Factors; Vasoconstriction | 2006 |
Clinical characteristics and outcomes of Chinese patients with cholesterol crystal embolism after coronary intervention.
Topics: Acute Kidney Injury; Aged; Angioplasty, Balloon, Coronary; Arteriosclerosis; Atorvastatin; China; Coronary Angiography; Embolism, Cholesterol; Female; Heptanoic Acids; Humans; Hypolipidemic Agents; Male; Prognosis; Prospective Studies; Pyrroles; Risk Assessment; Risk Factors; Simvastatin; Treatment Outcome | 2006 |
HMG-CoA reductase inhibition improves anti-aging klotho protein expression and arteriosclerosis in rats with chronic inhibition of nitric oxide synthesis.
Topics: Animals; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Glucuronidase; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Klotho Proteins; Male; Nitric Oxide Synthase; Pyrroles; Quinolines; Rats; Rats, Wistar | 2008 |
Atorvastatin has hypolipidemic and anti-inflammatory effects in apoE/LDL receptor-double-knockout mice.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aorta; Apolipoproteins E; Arteriosclerosis; Atorvastatin; Blotting, Western; Chemokine CCL2; Diet, Atherogenic; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Female; Heptanoic Acids; Hypolipidemic Agents; Intercellular Adhesion Molecule-1; Lipids; Mice; Mice, Knockout; Myocardium; Pyrroles; Receptors, LDL | 2008 |
Levels of soluble cell adhesion molecules in patients with dyslipidemia.
Topics: Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Cell Adhesion Molecules; Colestipol; Drug Therapy, Combination; E-Selectin; Endothelium, Vascular; Enzyme Inhibitors; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertriglyceridemia; Hypolipidemic Agents; Intercellular Adhesion Molecule-1; Lovastatin; Male; Middle Aged; Pyrroles; Risk Factors; Simvastatin; Solubility; Vascular Cell Adhesion Molecule-1 | 1996 |
[Lowering cholesterol. New concepts with atorvastatin].
Topics: Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Cholesterol; Clinical Trials as Topic; Heptanoic Acids; Humans; Hypercholesterolemia; Hyperlipoproteinemia Type II; Lipids; Pyrroles; Treatment Outcome | 1997 |
Therapy and clinical trials.
Topics: Antioxidants; Arteriosclerosis; Atorvastatin; Clinical Trials as Topic; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrroles; Vitamin A; Vitamin E | 1998 |
Nitric oxide synthase II (NOS II) gene expression correlates with atherosclerotic intimal thickening. Preventive effects of HMG-CoA reductase inhibitors.
Topics: Animals; Arteriosclerosis; Atorvastatin; Chemokine CCL2; Cholesterol; Cholesterol, Dietary; Disease Models, Animal; DNA; Down-Regulation; Fibrinogen; Gene Expression; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Macrophages; Muscle, Smooth, Vascular; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Polymerase Chain Reaction; Pyrroles; Rabbits; Simvastatin; Tunica Intima | 1999 |
Efficacy of vitamin E compared with either simvastatin or atorvastatin in preventing the progression of atherosclerosis in homozygous familial hypercholesterolemia.
Topics: Adolescent; Adult; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Carotid Arteries; Child; Child, Preschool; Cholesterol, HDL; Cholesterol, LDL; Disease Progression; DNA; Female; Heptanoic Acids; Homozygote; Humans; Hyperlipoproteinemia Type II; Male; Mutation; Pyrroles; Receptors, LDL; Simvastatin; Treatment Outcome; Triglycerides; Tunica Intima; Vitamin E | 1999 |
Regression of poloxamer 407-induced atherosclerotic lesions in C57BL/6 mice using atorvastatin.
Topics: Analysis of Variance; Animals; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Cholesterol, Dietary; Cholesterol, LDL; Culture Techniques; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Female; Heptanoic Acids; Injections, Intraperitoneal; Liver; Mice; Mice, Inbred C57BL; Poloxamer; Pyrroles; Reference Values; Remission Induction; Triglycerides | 2000 |
Systemic cause of unstable atherosclerotic plaques. Atorvastatin and Thrombogenicity of Carotid Atherosclerotic Plaque (ATROCAP) study group.
Topics: Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Carotid Stenosis; Cause of Death; Heptanoic Acids; Humans; Pyrroles; Risk Factors | 2000 |
Pleiotropic effects of statins in atherosclerosis and diabetes.
Topics: Animals; Arteriosclerosis; Atorvastatin; Cell Division; Cell Movement; Cells, Cultured; Cholesterol; Cholesterol Esters; Diabetes Complications; Diabetes Mellitus; Diabetic Angiopathies; Endocytosis; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lipoproteins; Lovastatin; Macrophages; Macrophages, Peritoneal; Mice; Mice, Inbred BALB C; Muscle, Smooth; Pyridines; Pyrroles; Simvastatin | 2000 |
Status report of lipid-lowering trials in diabetes.
Topics: Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Clinical Trials as Topic; Coronary Disease; Diabetes Mellitus, Type 2; Fenofibrate; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Pyrroles; Risk Factors | 2000 |
Lipid treatment goals achieved in patients treated with statin drugs in Norwegian general practice.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Cross-Sectional Studies; Family Practice; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lipids; Male; Middle Aged; Norway; Pravastatin; Pyridines; Pyrroles; Retrospective Studies; Simvastatin; Surveys and Questionnaires | 2000 |
Lipid modulation and atherosclerotic events: extending the clinical spectrum with fibrates and statins.
Topics: Adult; Aged; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Clinical Trials as Topic; Evidence-Based Medicine; Gemfibrozil; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Middle Aged; Myocardial Revascularization; Preventive Medicine; Pyrroles | 2000 |
What have we learned about the biology of atherosclerosis? The role of inflammation.
Topics: Animals; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Cholesterol, Dietary; Coronary Artery Disease; Coronary Stenosis; Heptanoic Acids; Humans; Inflammation Mediators; Pyrroles; Rabbits | 2001 |
Raman spectroscopic evaluation of the effects of diet and lipid-lowering therapy on atherosclerotic plaque development in mice.
Topics: Animals; Anticholesteremic Agents; Aorta; Apolipoprotein E3; Apolipoproteins E; Arteriosclerosis; Atorvastatin; Calcinosis; Cholesterol; Diet, Atherogenic; Disease Progression; Female; Heptanoic Acids; Male; Mice; Mice, Transgenic; Pyrroles; Reproducibility of Results; Spectrum Analysis, Raman; Treatment Outcome | 2001 |
HMG-CoA reductase inhibitors reduce vascular monocyte chemotactic protein-1 expression in early lesions from hypercholesterolemic swine independently of their effect on plasma cholesterol levels.
Topics: Animals; Aorta; Arteries; Arteriosclerosis; Atorvastatin; Carotid Arteries; Chemokine CCL2; Cholesterol; Coronary Vessels; Down-Regulation; Femoral Artery; Gene Expression; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Iliac Artery; Immunohistochemistry; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Pravastatin; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Swine | 2001 |
Atorvastatin reduces the expression of cyclooxygenase-2 in a rabbit model of atherosclerosis and in cultured vascular smooth muscle cells.
Topics: Animals; Arteriosclerosis; Atorvastatin; Cells, Cultured; Cyclooxygenase 1; Cyclooxygenase 2; Disease Models, Animal; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-8; Isoenzymes; Lipids; Macrophages; Male; Matrix Metalloproteinases; Muscle, Smooth, Vascular; NF-kappa B; Prostaglandin-Endoperoxide Synthases; Protein Isoforms; Pyrroles; Rabbits; Random Allocation; Randomized Controlled Trials as Topic; Time Factors | 2002 |
The effects of lipid-lowering therapy on low-density lipoprotein auto-antibodies: relationship with low-density lipoprotein oxidation and plasma total antioxidant status.
Topics: Adult; Aged; Antioxidants; Apolipoproteins; Arteriosclerosis; Atorvastatin; Autoantibodies; Female; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Immunoassay; Lipids; Lipoproteins; Lipoproteins, LDL; Male; Middle Aged; Oxidation-Reduction; Pyrroles | 2002 |